Patient‐derived tumour xenografts and tumour organoids have become important preclinical
model systems for cancer research. Both models maintain key features from their parental …

Progress in oncology drug development has been hampered by a lack of preclinical models
that reliably predict clinical activity of novel compounds in cancer patients. In an effort to …

The majority of human solid tumours do not metastasize when grown subcutaneously in
immunocompromised mice; this includes patient-derived xenograft (PDX) models. However …

Cancers remain a major public health problem worldwide, which still require profound
research in both the basic and preclinical fields. Patient-derived xenograft (PDX) models are …

Pancreatic cancer is one of the deadliest human cancers, whose progression is highly
dependent on the nervous microenvironment. The suppression of gene expression of nerve …

Pancreatic cancer (PC) has exceptionally high mortality due to ineffective treatment
strategies. Immunotherapy, which mobilizes the immune system to fight against cancer, has …

Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive type of cancer with
an overall survival rate of less than 7-8%, emphasizing the need for novel effective …

Pancreatic ductal adenocarcinoma (PDA) is a highly lethal malignancy for which new
treatment and diagnostic approaches are urgently needed. For such breakthroughs to be …

For decades, xenografts using well-established human tumor cell lines have been the most
commonly used models to study human cancers in mice. More recently, human tumors …

Currently used rodent tumor models, including transgenictumor models, or subcutaneously-
growing human tumors inimmunodeficient mice, do not sufficiently represent clinicalcancer …